2 results
Approved WMOCompleted
The primary objectives of the trial are to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-Neb for 12 months, compared to placebo in subjects with non*cystic fibrosis bronchiectasis (NCFB)…
Approved WMOCompleted
The primary outcome of the study is a 50% reduction in exacerbation rate in patients using TIS once daily (OD). Secondary outcome parameters are lung function (FEV1, FVC), QoL (QOL-B), LTRI-VAS, Leicester cough score), bacterial load in sputum and…